Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. (Q33383770)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19297314%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19297314%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

Gedske Daugaard

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19297314%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19297314%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19297314%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

C N Sternberg

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19297314%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

H Dumez

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19297314%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

H Van Poppel

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19297314%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

I Skoneczna

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19297314%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

A Sella

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19297314%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

T Gil

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19297314%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

P Carpentier

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19297314%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

L Collette

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19297314%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

D Lacombe

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19297314%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

EORTC Genitourinary Tract Cancer Group

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19297314%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

17 March 2009

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19297314%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19297314%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19297314%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1264-1269

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19297314%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19297314%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN784

21 January 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN784

21 January 2018

Current indications for chemotherapy in prostate cancer patients.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN784

21 January 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN784

21 January 2018

State-of-the-art treatment of metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN784

21 January 2018

A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN784

21 January 2018

A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN784

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN784

21 January 2018

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN784

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33383770&oldid=1990958730"